Acute Ischemic Stroke Clinical Trial
Official title:
Head-of-Bed Positioning in Large Artery Acute Ischemic Stroke
Positioning of the patient with hyperacute large artery ischemic stroke (IS) is an important, yet understudied aspect of care that could impact the course of treatment and ultimately clinical outcome. Positioning with the head of bed (HOB) at 0-degree has been shown in small studies to increase cerebral blood flow across arterial occlusion in hyperacute large artery IS, leading to clinical improvement in stroke symptoms. However, this position is believed to increase the risk of aspiration pneumonia. In this randomised clinical trial, the investigators aim to evaluate whether use of 0-degree HOB positioning is associated with clinical stability in hyperacute IS. Investigators hypothesise that patients with large artery occlusions placed in a 0-degree HOB position will experience less early neurologic deterioration within the first 24 hours, than those in the 30-degree or more HOB elevation group. The study aims to confirm the safety of 0-degree-HOB positioning in a large, generalizable sample of hyperacute large artery IS patients. In this randomised trial, patients presenting to the study centers and eligible for intravenous thrombolysis, with (if presenting within 4.5 hours of symptom-onset) or without (presenting between 4.5 to 16 hours of symptom-onset) mechanical thrombectomy. Eligible patients would be randomised to either a zero-degree HOB or an HOB of 30-degree or more. Impact of HOB position on neurological status would be evaluated with serial NIHSS scores. Cerebral hemodynamics would be monitored by transcranial Doppler ultrasonography. Validated criteria would be used to diagnose pneumonia. Functional outcome would be measured by modified Rankin scale (mRS) where the score of 0-2 describe good functional recovery. SPSS version 20 would be used to analyse the data. The trial would provide clinical and hemodynamic data to determine the optimal HOB position in patients with large artery acute ischemic stroke.
Status | Recruiting |
Enrollment | 182 |
Est. completion date | April 30, 2024 |
Est. primary completion date | March 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years and older |
Eligibility | Inclusion Criteria: - • Ischemic stroke symptoms consistent with large artery occlusion - Baseline non-contrast head CT (or MRI) negative for hemorrhage or mass- effect - Evidence of arterial occlusion on standard of care CT angiography or MR angiography or NIHSS 10 or more points - Alberta Stroke Program Early Computed Tomography Score [ASPECTS] >6 - Patients treated with IV-tPA, mechanical thrombectomy or both - Pre-stroke baseline modified Rankin Score (mRS) <1 - Ability to enrol, randomize and begin the intervention within the Emergency Department Exclusion Criteria: - • Pregnancy or suspicion of pregnancy - Evidence or suspicion of vomiting any time prior to consent which could predispose to aspiration pneumonia and therefore confound determination of protocol safety - Evidence of evolving malignant infarction on admission noncontrast CT (or MRI) - Need for intubation with mechanical ventilation, or non-invasive ventilatory support with either bi-level positive airway pressure (BiPAP) or continuous positive airway pressure (CPAP) - Inability to tolerate zero-degree positioning due to congestive heart failure, preexisting pneumonia, chronic obstructive pulmonary disease, or other medical condition - Admission chest radiograph positive for pleural effusion, pulmonary edema, pneumonia, or other pulmonary condition that may confound determination of protocol safety - Abnormal breath sounds on that may confound determination of protocol safety |
Country | Name | City | State |
---|---|---|---|
Singapore | Division of Neurology, National University Hospital | Singapore | |
Singapore | National University Hospital | Singapore |
Lead Sponsor | Collaborator |
---|---|
National University of Singapore |
Singapore,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | National Institute of Health Stroke Scale (NIHSS) change (higher change means more improvement) at day-7 and modified Rankin Score (mRS) at day-7 | Investigators will analyze the data by dichotomized modified Rankin Score (mRS) 0-2 (good functional outcome) versus 3-6 (poor outcome) as well as mrs 0-1 (excellent outcome) versus mRS 2-6 (unfavorable outcome) as well as ordinal shift across the range of mRS 0-6 | day-7 | |
Primary | National Institute of Health Stroke Scale (NIHSS) change (higher value indicate more improvement) at day-90 and modified Rankin Score (mRS) at day-90 | Investigators will analyze the data by dichotomized mRS (0-2 as good functional outcome versus 3-6 as poor outcome), mRS (0-1 as excellent functional outcome versus 2-6 as unfavorable outcome) as well as ordinal shift across entire range of mRS 0-6. | day-90 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06113848 -
Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy
|
Phase 3 | |
Completed |
NCT04069546 -
The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency
|
N/A | |
Active, not recruiting |
NCT05700097 -
Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy
|
Phase 2 | |
Recruiting |
NCT06058130 -
Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis
|
N/A | |
Recruiting |
NCT04415164 -
Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke
|
Phase 4 | |
Recruiting |
NCT05363397 -
Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke
|
Phase 2 | |
Completed |
NCT05429658 -
Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System
|
N/A | |
Recruiting |
NCT05390580 -
Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct
|
N/A | |
Enrolling by invitation |
NCT05515393 -
A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
|
Phase 2 | |
Active, not recruiting |
NCT05070260 -
ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo
|
Phase 2/Phase 3 | |
Terminated |
NCT05547412 -
Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
|
||
Completed |
NCT03366818 -
New Stent Retriever, VERSI System for AIS
|
N/A | |
Not yet recruiting |
NCT05293080 -
Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE
|
Phase 3 | |
Not yet recruiting |
NCT06040476 -
Human Umbilical Cord Blood Infusion in Patients With Acute Ischemic Stroke (AIS)
|
Phase 2 | |
Not yet recruiting |
NCT06437431 -
Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy
|
Phase 2/Phase 3 | |
Completed |
NCT02223273 -
Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke)
|
N/A | |
Completed |
NCT02586233 -
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT01594190 -
Physical Activity Immediately After Acute Cerebral Ischemia
|
N/A | |
Terminated |
NCT01694381 -
Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor
|
Early Phase 1 | |
Completed |
NCT01120301 -
Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3)
|
Phase 3 |